306 related articles for article (PubMed ID: 37056782)
21. Immune infiltration profiling in gastric cancer and their clinical implications.
Ren F; Zhao Q; Zhao M; Zhu S; Liu B; Bukhari I; Zhang K; Wu W; Fu Y; Yu Y; Tang Y; Zheng P; Mi Y
Cancer Sci; 2021 Sep; 112(9):3569-3584. PubMed ID: 34251747
[TBL] [Abstract][Full Text] [Related]
22. Human CD4
Šunina M; Alnek K; Kisand K; Uibo R
Scand J Immunol; 2021 Sep; 94(3):e13089. PubMed ID: 35971920
[TBL] [Abstract][Full Text] [Related]
23. Single-cell RNA sequencing indicates cordycepin remodels the tumor immune microenvironment to enhance TIGIT blockade's anti-tumor effect in colon cancer.
Chen R; Feng C; Chen L; Zheng X; Fang W; Wu S; Gao X; Chen C; Yang J; Wu Y; Chen Y; Zheng P; Hu N; Yuan M; Fu Y; Ying H; Zhou J; Jiang J
Int Immunopharmacol; 2024 Jan; 126():111268. PubMed ID: 37992442
[TBL] [Abstract][Full Text] [Related]
24. TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer.
Xu D; Zhao E; Zhu C; Zhao W; Wang C; Zhang Z; Zhao G
Immunobiology; 2020 May; 225(3):151915. PubMed ID: 32122675
[TBL] [Abstract][Full Text] [Related]
25. CD226 opposes TIGIT to disrupt Tregs in melanoma.
Fourcade J; Sun Z; Chauvin JM; Ka M; Davar D; Pagliano O; Wang H; Saada S; Menna C; Amin R; Sander C; Kirkwood JM; Korman AJ; Zarour HM
JCI Insight; 2018 Jul; 3(14):. PubMed ID: 30046006
[TBL] [Abstract][Full Text] [Related]
26. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8
Weulersse M; Asrir A; Pichler AC; Lemaitre L; Braun M; Carrié N; Joubert MV; Le Moine M; Do Souto L; Gaud G; Das I; Brauns E; Scarlata CM; Morandi E; Sundarrajan A; Cuisinier M; Buisson L; Maheo S; Kassem S; Agesta A; Pérès M; Verhoeyen E; Martinez A; Mazieres J; Dupré L; Gossye T; Pancaldi V; Guillerey C; Ayyoub M; Dejean AS; Saoudi A; Goriely S; Avet-Loiseau H; Bald T; Smyth MJ; Martinet L
Immunity; 2020 Oct; 53(4):824-839.e10. PubMed ID: 33053331
[TBL] [Abstract][Full Text] [Related]
27. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8
Banta KL; Xu X; Chitre AS; Au-Yeung A; Takahashi C; O'Gorman WE; Wu TD; Mittman S; Cubas R; Comps-Agrar L; Fulzele A; Bennett EJ; Grogan JL; Hui E; Chiang EY; Mellman I
Immunity; 2022 Mar; 55(3):512-526.e9. PubMed ID: 35263569
[TBL] [Abstract][Full Text] [Related]
28. CMA1 is potent prognostic marker and associates with immune infiltration in gastric cancer.
Shi S; Ye S; Mao J; Ru Y; Lu Y; Wu X; Xu M; Zhu T; Wang Y; Chen Y; Tang X; Xi Y
Autoimmunity; 2020 Jun; 53(4):210-217. PubMed ID: 32129682
[No Abstract] [Full Text] [Related]
29. Perturbed CD8
Tauriainen J; Scharf L; Frederiksen J; Naji A; Ljunggren HG; Sönnerborg A; Lund O; Reyes-Terán G; Hecht FM; Deeks SG; Betts MR; Buggert M; Karlsson AC
Sci Rep; 2017 Jan; 7():40354. PubMed ID: 28084312
[TBL] [Abstract][Full Text] [Related]
30. Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
Lee MH; Theodoropoulos J; Huuhtanen J; Bhattacharya D; Järvinen P; Tornberg S; Nísen H; Mirtti T; Uski I; Kumari A; Peltonen K; Draghi A; Donia M; Kreutzman A; Mustjoki S
Cancer Res Commun; 2023 Jul; 3(7):1260-1276. PubMed ID: 37484198
[TBL] [Abstract][Full Text] [Related]
31. Increased tumor-infiltrating CD45RA
Mao FY; Kong H; Zhao YL; Peng LS; Chen W; Zhang JY; Cheng P; Wang TT; Lv YP; Teng YS; Fu XL; Liu YG; Wu XL; Hao CJ; You N; Luo P; Yu PW; Zou QM; Guo G; Zhuang Y
Cell Death Dis; 2017 Aug; 8(8):e3002. PubMed ID: 28817117
[TBL] [Abstract][Full Text] [Related]
32. Single-cell analysis of localized prostate cancer patients links high Gleason score with an immunosuppressive profile.
Adorno Febles VR; Hao Y; Ahsan A; Wu J; Qian Y; Zhong H; Loeb S; Makarov DV; Lepor H; Wysock J; Taneja SS; Huang WC; Becker DJ; Balar AV; Melamed J; Deng FM; Ren Q; Kufe D; Wong KK; Adeegbe DO; Deng J; Wise DR
Prostate; 2023 Jun; 83(9):840-849. PubMed ID: 36988342
[TBL] [Abstract][Full Text] [Related]
33. Tumor-infiltrating lymphocyte: features and prognosis of lymphocytes infiltration on colorectal cancer.
Qin M; Chen G; Hou J; Wang L; Wang Q; Wang L; Jiang D; Hu Y; Xie B; Chen J; Wei H; Xu G
Bioengineered; 2022 Jun; 13(6):14872-14888. PubMed ID: 36633318
[TBL] [Abstract][Full Text] [Related]
34. LAG3 blockade coordinates with microwave ablation to promote CD8
Shao D; Chen Y; Huang H; Liu Y; Chen J; Zhu D; Zheng X; Chen L; Jiang J
J Transl Med; 2022 Sep; 20(1):433. PubMed ID: 36180876
[TBL] [Abstract][Full Text] [Related]
35. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
[TBL] [Abstract][Full Text] [Related]
36. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
[TBL] [Abstract][Full Text] [Related]
37. Diffuse large B-cell lymphoma: the significance of CD8
Zhu Q; Yang Y; Chen K; Zhang Q; Huang Y; Jian S
J Transl Med; 2024 Feb; 22(1):174. PubMed ID: 38369502
[TBL] [Abstract][Full Text] [Related]
38. Alteration of CD226/TIGIT immune checkpoint on T cells in the pathogenesis of primary Sjögren's syndrome.
Deng C; Chen Y; Li W; Peng L; Luo X; Peng Y; Zhao L; Wu Q; Zhang W; Zhang X; Fei Y
J Autoimmun; 2020 Sep; 113():102485. PubMed ID: 32466852
[TBL] [Abstract][Full Text] [Related]
39. CD226
Jin HS; Ko M; Choi DS; Kim JH; Lee DH; Kang SH; Kim I; Lee HJ; Choi EK; Kim KP; Yoo C; Park Y
Cancer Immunol Res; 2020 Jul; 8(7):912-925. PubMed ID: 32265229
[TBL] [Abstract][Full Text] [Related]
40. Direct AKT activation in tumor-infiltrating lymphocytes markedly increases interferon-γ (IFN-γ) for the regression of tumors resistant to PD-1 checkpoint blockade.
Santinon F; Ezzahra BF; Bachais M; Sarabia Pacis A; Rudd CE
Sci Rep; 2022 Nov; 12(1):18509. PubMed ID: 36323740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]